Metsera, Inc. is a biopharmaceutical company focused on developing peptide-based medicines for obesity and other metabolic and cardiometabolic diseases. The company aims to address unmet needs in weight management and related metabolic conditions through hormone-inspired therapeutics.
Metsera’s pipeline spans discovery through development and is built on peptide engineering, optimization, and formulation capabilities. Its R&D centers on creating long-acting, selective therapeutics intended to improve efficacy and tolerability in metabolic disease treatment.
Novo Nordisk maintains its offer for Metsera, citing financial discipline and strategic goals, despite previous revisions and competitive considerations.
Novo Nordisk's updated proposal for Metsera is deemed superior, offering $62.20/share plus CVRs. The deal aligns with Novo's strategy to expand in obesity and diabetes treatment.
Novo Nordisk offers $56.50 per share for Metsera, with potential CVRs up to $21.25 based on milestones. The proposal awaits Metsera board review.
